Vandana Singh - Spark Newswire

1 minute read

Revolution Medicines’ Early-Data Validation For Cancer Program Wins Price Target Boost By This Analyst

Today, 10:32 PM

Needham increased the price target for Revolution Medicines Inc (NASDAQ:RVMD) from $32 to $38 with a Buy rating. In its Q4 earnings release, Revolution…

RVMD

1 minute read

Analysts Remain Bullish On SI-BONE, Forecast Q4’s Strength To Continue In 2023

By Vandana Singh

Today, 10:32 PM

SI-BONE Inc (NASDAQ:SIBN) reported a Q4 EPS loss of $(0.32), beating the consensus of $(0.40) and sales of $31.95 million,…

SIBN

1 minute read

Merck Discontinues Two Keytruda Combo Therapy Trials In Prostate & Lung Cancer Settings

By Vandana Singh

Today, 10:32 PM

Merck & Co Inc (NYSE:MRK) is discontinuing the Phase 3 KEYNOTE-641 trial evaluating Keytruda (pembrolizumab) in combination with enzalutamide and androgen…

MRK

1 minute read

AdaptHealth’s Q4 Core Earnings Fall Short Of Expectations, Trims Annual Guidance

By Vandana Singh

Today, 10:32 PM

AdaptHealth Corp (NASDAQ:AHCO) delivered Q4 revenue of $780.28 million, +11.1% Y/Y, including non-acquired growth of 5.3%, missing the consensus of…

AHCO

2 minute read

BioMarin Hints Probable Delay For US Approval For Roctavian, But Analyst Convinced For Transformative 2023

By Vandana Singh

Today, 10:32 PM

Biomarin Pharmaceutical Inc (NASDAQ:BMRN) reported a break-even in Q4 FY22 compared to a loss of $(0.32) a year ago and the…

BMRN

2 minute read

Swiss Regulatory Authority Find Credit Suisse In Serious Violation Regarding Greensill Debacle

By Vandana Singh

Today, 10:32 PM

The Swiss Financial Market Supervisory Authority FINMA has concluded its enforcement proceedings against Credit Suisse Group AG (NYSE:CS) concerning its business relationship…

1 minute read

Analyst Says This Small Cap Biotech Firm Has ‘Very Valuable Therapeutic,’ Upgrades Stock

By Vandana Singh

Today, 10:32 PM

Raymond James has upgraded Dyne Therapeutics Inc (NASDAQ:DYN) from Outperform to Strong Buy and raised the price target to $27 from $16.…

DYN

1 minute read

Dr. Reddy’s Seeks Gaining Foothold In Women’s Health Via Mayne Pharma’s U.S. Generic Prescription Deal

By Vandana Singh

Today, 10:32 PM

Dr. Reddy’s Laboratories Ltd (NYSE:RDY) has agreed to acquire the U.S. generic prescription product portfolio of Australia-based Mayne Pharma Group Limited (OTC:MAYND) (OTC:MAYNF)…

MAYND